Welcome to the 2nd Annual Gene Therapy Medical Affairs Summit
In April this year, we will be uniting global Medical Affairs leads at the 2nd Annual Gene Therapy Medical Affairs Summit, the industry’s definitive and only meeting focused on tackling the greatest challenges associated with medical communication, education, market access and product launch within the gene therapy field.
We will explore how to optimise the pivotal internal and external role Medical Affairs plays in preparing for successful and patient-centric gene therapy launches. Equipping you with actionable insights required to optimise the medical affairs approaches from early development of gene therapies right the way through to a launch environment to ensure market readiness.
Hear from the likes of Orchard Therapeutics, Spark Therapeutics and Sanofi across 3 days of in-depth case studies, interactive panel discussions, dedicated Q&A time, and networking opportunities to meet and learn how the leaders in the field are reinforcing the value of medical affairs teams.
See What You Missed:
Global Medical Affairs leads from Astellas Gene Therapies are transforming from reactive to proactive strategic partners to launch gene therapy products more efficiently and effectively than ever before
Orchard Therapeutics and PTC Therapeutics are defining both the role and value of Medical Affairs to optimise your activity from early development right the way through to a launch environment and ensure market readiness
Pfizer are collecting long term data on safety, variability and durability of efficacy of gene therapies to reinforce your understanding of gene therapy outcomes and their impact on the lives of patients with rare diseases
ASC Therapeutics and Sanofi Genzyme are upskilling internal cross-functional teams to ensure internal alignment on the medical strategy and improve field team readiness